RxDoctor Payments Data

Charles Lichty, MD

Internal Medicine · Birmingham, ALNPI 1487627766

Payments from drug & device makers

$4,559in general payments, 2019–2025

Across 283 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$674
  • AbbVie$439
  • Lilly USA, LLC$371
  • AstraZeneca$254
  • Astellas Pharma US Inc$220
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,43797%
  • Education$1223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,559 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$245,574
Medicare patients
386
Services billed
8,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide133$141,137
OzempicSemaglutide137$131,740
EliquisApixaban103$120,371
JardianceEmpagliflozin73$74,737
Janumet XrSitagliptin Phos/Metformin Hcl78$59,841
FarxigaDapagliflozin Propanediol75$58,892
JanuviaSitagliptin Phosphate52$53,581
XareltoRivaroxaban39$34,825
TrulicityDulaglutide26$33,455
LinzessLinaclotide31$32,329
JanumetSitagliptin Phos/Metformin Hcl22$22,258
EntrestoSacubitril/Valsartan11$16,921
MyrbetriqMirabegron15$16,138
Lantus SolostarInsulin Glargine,hum.Rec.Anlog106$15,476
GemtesaVibegron25$14,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$371$174,592159 claims
MerckJanumet Xr, Januvia, Janumet$49$135,681152 claims
Novo NordiskOzempic$1,256$131,740137 claims
PfizerEliquis$674$120,371103 claims
Boehringer IngelheimJardiance, Synjardy Xr$162$87,96987 claims
AstraZenecaFarxiga$254$58,89275 claims
AbbVieLinzess, Synthroid$439$36,63897 claims
Johnson & JohnsonXarelto$67$34,82539 claims
NovartisEntresto$98$16,92111 claims
Astellas Pharma US IncMyrbetriq$220$16,13815 claims
Sumitomo Pharma America, Inc.Gemtesa$28$14,37525 claims
GSKBreo Ellipta$198$12,05021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →